scholarly journals Cancer Therapy: TPGS-Functionalized Polydopamine-Modified Mesoporous Silica as Drug Nanocarriers for Enhanced Lung Cancer Chemotherapy against Multidrug Resistance (Small 29/2017)

Small ◽  
2017 ◽  
Vol 13 (29) ◽  
Author(s):  
Wei Cheng ◽  
Chaoyu Liang ◽  
Lv Xu ◽  
Gan Liu ◽  
Nansha Gao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Multidrug Resistance ◽  
Cancer Therapy ◽  
Mesoporous Silica ◽  
Cancer Chemotherapy ◽  
Drug Nanocarriers

TPGS-Functionalized Polydopamine-Modified Mesoporous Silica as Drug Nanocarriers for Enhanced Lung Cancer Chemotherapy against Multidrug Resistance

Small ◽  
2017 ◽  
Vol 13 (29) ◽  
pp. 1700623 ◽  
Author(s):  
Wei Cheng ◽  
Chaoyu Liang ◽  
Lv Xu ◽  
Gan Liu ◽  
Nansha Gao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Multidrug Resistance ◽  
Mesoporous Silica ◽  
Cancer Chemotherapy ◽  
Drug Nanocarriers

Combinatorial delivery of targeted mesoporous silica nanoparticles for lung cancer therapy

2016 ◽  
Author(s):  
Deniz Ali Bölükbas ◽  
Stefan Datz ◽  
Charlotte Meyer-Schwickerath ◽  
Malamati Vreka ◽  
Sabine van Rijt ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Lung Cancer Therapy

Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy

2014 ◽  
Vol 275 (3) ◽  
pp. 232-243 ◽  
Author(s):  
Shenbagamoorthy Sundarraj ◽  
Ramar Thangam ◽  
Mohanan V. Sujitha ◽  
Karuppaiya Vimala ◽  
Soundarapandian Kannan
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Mesoporous Silica ◽  
Delivery System ◽  
Lung Cancer Therapy

Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications

2020 ◽  
Vol 20 (4) ◽  
pp. 271-287 ◽  
Author(s):  
Kuldeep Rajpoot
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Adverse Effects ◽  
Targeted Drug Delivery ◽  
Tumor Therapy ◽  
Cancer Therapies ◽  
Medication Delivery ◽  
Lipid Nanocarriers ◽  
Targeted Drug ◽  
Drug Nanocarriers

Though modern available cancer therapies are effective, they possess major adverse effects, causing non-compliance to patients. Furthermore, the majority of the polymeric-based medication platforms are certainly not universally acceptable, due to their several restrictions. With this juxtaposition, lipid-based medication delivery systems have appeared as promising drug nanocarriers to replace the majority of the polymer-based products because they are in a position to reverse polymer as well as, drug-associated restrictions. Furthermore, the amalgamation of the basic principle of nanotechnology in designing lipid nanocarriers, which are the latest form of lipid carriers, has tremendous chemotherapeutic possibilities as tumor-targeted drug-delivery pertaining to tumor therapy. Apart from this, it is reported that nearly 40% of the modern medication entities are lipophilic. Moreover, research continues to be efficient in attaining a significant understanding of the absorption and bioavailability of the developed lipids systems.

Sign in / Sign up

Export Citation Format

Share Document